Morgan Stanley Stock News

Morgan Stanley''s 2022 Outlook: The Training Wheels Come Off By Andrew Sheets, Chief Cross-Asset Strategist for Morgan Stanley The 2022 Outlook: Normalizing but Not Normal, as the Training Wheels Come Off Well publish our year-ahead outlook later today. This is the 18th outlook Ive had the pleasure to be a part of in Morgan Stanley Research. Each one is the result of a highly collaborative process across strategy and economics, and each has felt uniquely difficult at the time. 2022 is no different. In the global economy, my colleague Seth Carpenter and our global economics team think it is a story of ''normalizing, but not normal''. Normalizing, because we think global growth continues to improve, led by strong consumer spending and capital investment. We forecast growth of 4.6%Y in both the US and euro area next year, and think China will also top expectations, albeit with improvement that may not be apparent for several more months. A robust capex cycle, driven by strong demand, rising labor costs and cheap capital, is an important way this recovery differs from the last.

AES (NYSE:AES) updated its FY 2021 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $1.500-$1.580 for the period, compared to the Thomson Reuters consensus estimate of $1.550. The company issued revenue guidance of -. A number of equities analysts recently issued reports on the company. Morgan Stanley increased their price []

Commentary from MS on cable:

Morgan Stanley lifted its stake in shares of Range Resources Co. (NYSE:RRC) by 87.4% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,754,998 shares of the oil and gas exploration companys stock after buying an additional 818,687 shares during the period. []

Cricut (NASDAQ:CRCT) had its price target trimmed by Morgan Stanley from $29.00 to $20.00 in a report issued on Thursday, The Fly reports. The firm currently has an underweight rating on the stock. A number of other analysts have also weighed in on the stock. Zacks Investment Research raised shares of Cricut from a strong []

General Motors (NYSE:GM) (TSE:GMM.U) had its target price reduced by Morgan Stanley from $80.00 to $75.00 in a research note released on Thursday morning, The Fly reports. They currently have an overweight rating on the auto manufacturers stock. The analysts noted that the move was a valuation call. A number of other brokerages have also []

Live Nation Entertainment (NYSE:LYV) had its price objective raised by Citigroup from $98.00 to $116.00 in a research note released on Thursday morning, PriceTargets.com reports. Citigroup currently has a neutral rating on the stock. Several other brokerages have also recently commented on LYV. Morgan Stanley boosted their price target on shares of Live Nation Entertainment []

Integral Ad Science (NASDAQ:IAS) had its target price lifted by Raymond James from $22.00 to $28.00 in a research report released on Thursday morning, Analyst Ratings Network reports. They currently have an outperform rating on the stock. Several other equities analysts have also recently issued reports on the stock. Morgan Stanley upped their price target []

Veracyte (NASDAQ:VCYT) had its price objective increased by Raymond James from $50.00 to $62.00 in a research report sent to investors on Wednesday morning, The Fly reports. Raymond James currently has an outperform rating on the biotechnology companys stock. VCYT has been the topic of several other research reports. Morgan Stanley lowered their target price []

Palantir Technologies (NYSE:PLTR) had its target price raised by Morgan Stanley from $22.00 to $24.00 in a research note released on Wednesday, The Fly reports. They currently have an underweight rating on the stock. Other analysts have also issued research reports about the company. Royal Bank of Canada lowered Palantir Technologies from a sector perform []

Morgan Stanley boosted its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 1,107.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,129,478 shares of the companys stock after purchasing an additional 1,035,898 shares during the period. Morgan Stanley owned about 0.79% of []

Morgan Stanley lessened its stake in Invesco China Technology ETF (NYSEARCA:CQQQ) by 2.8% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 346,011 shares of the companys stock after selling 9,918 shares during the period. Morgan Stanleys holdings in Invesco China Technology ETF were worth $29,134,000 at the []

Morgan Stanley reduced its holdings in H&R Block, Inc. (NYSE:HRB) by 23.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,240,597 shares of the companys stock after selling 389,601 shares during the quarter. Morgan Stanley owned about 0.68% of H&R Block []

Hookipa Pharma (NASDAQ:HOOK) was downgraded by stock analysts at Morgan Stanley from an overweight rating to an equal weight rating in a research note issued on Friday, Price Targets.com reports. They currently have a $6.00 target price on the stock. Morgan Stanleys price objective suggests a potential upside of 43.88% from the stocks previous close. []